Sathgen Therapeutics

Mumbai, India Founded: 2007 • Age: 19 yrs Listed
Clinical-stage biotech firm developing cancer treatments and antiviral drugs through trials.
Request Access
Report Incorrect Data
Page last updated

About Sathgen Therapeutics

Sathgen Therapeutics is a publicly listed company based in Mumbai (India) founded in 2007. Clinical-stage biotech firm developing cancer treatments and antiviral drugs through trials. It operates on a B2B model. The company has 1,482 employees. Its Indian entity Godavari Biorefineries Limited reported revenue of ₹2,000 Cr. Sathgen Therapeutics offers products and services including MSP008-22. Its focus areas include Biotechnology, Oncology, Cancer Therapeutics and Anti-Viral.

Company details

Sathgen Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative treatments for difficult-to-treat cancers and viral infections. They conduct clinical trials for their lead drug candidate, MSP008-22, to evaluate safety and efficacy. Backed by Godavari Biorefineries Limited, they use an integrated approach to target diseases as complex systems. Based in Mumbai, India, they collaborate with partners to improve patient quality of life.

Operational Areas
Healthcare → Immunology & Cancer Therapeutics
Healthcare → Cell Therapy
Key Metrics
  • Market Cap
    ₹1,044 Cr

    GODAVARIB · NSE

  • Share Price
    ₹205.10

    +0.58% today

  • Revenue
    ₹1,988 Cr

    FY 2025-26 · +6.3% YoY

  • EBITDA
    ₹95.98 Cr

    Margin 4.8%

  • Net Profit
    ₹33.63 Cr

    FY 2025-26 · +238.2% YoY

  • P/E (TTM)
    35.6x

    P/B 1.3x

  • Employee Count
    1,482

Products & Services of Sathgen Therapeutics

Sathgen Therapeutics offers a comprehensive portfolio of products and services, including MSP008-22.

MSP008-22
Oncology Drug

Treats advanced solid tumors and inhibits viral replication.

Board of directors of Godavari Biorefineries Limited (Sathgen Therapeutics)

Godavari Biorefineries Limited is the primary company behind Sathgen Therapeutics. The board of Godavari Biorefineries Limited currently have 12 directors; the longest-serving is Samir Shantilal Somaiya, appointed in 2007. 35 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Samir Shantilal Somaiya
DIN 00295458
Managing Director22 Jun 200719 yrs 4 moGodavari Biorefineries Limited
Lakshmi Kantam Mannepalli
DIN 07831607
Director28 Nov 20178 yrs 11 moGodavari Biorefineries Limited
Bhalachandra Raghavendra Bakshi
DIN 03538688
Whole-time director01 Jun 20188 yrs 5 moGodavari Biorefineries Limited
Hemant Luthra
DIN 00231420
Director27 Sep 20197 yrs 1 moGodavari Biorefineries Limited
Sangeeta Arunkumar Srivastava
DIN 00480462
Whole-time director01 Aug 20206 yrs 3 moGodavari Biorefineries Limited
Nitin Mehta
DIN 09174633
Director01 Jul 20215 yrs 4 moGodavari Biorefineries Limited
Suhas Uttam Godage
DIN 09227610
Whole-time director08 Sep 20215 yrs 1 moGodavari Biorefineries Limited
Raman Ramachandran
DIN 00200297
Director30 Nov 20232 yrs 11 moGodavari Biorefineries Limited
Kumar Desai
DIN 10729351
Director16 Sep 20242 yrs 1 moGodavari Biorefineries Limited
Nandan Dhananjay Mehta
DIN 07134249
Director30 Sep 20251 yr 1 moGodavari Biorefineries Limited
Sean Edward Reagan
DIN 01490812
Director30 Sep 20251 yr 1 moGodavari Biorefineries Limited
Dinesh
DIN 11675064
Whole-time director28 Sep 20261 moGodavari Biorefineries Limited

IPO & Listings of Sathgen Therapeutics

Sathgen Therapeutics is a publicly listed company on the NSE with ticker symbol GODAVARIB in India, operating in the Sugar sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: GODAVARIB
  • Listed entityGodavari Biorefineries Limited
  • Exchange sectorSugar

Financials of Sathgen Therapeutics

Exchange-reported figures of Godavari Biorefineries Limited, the listed company behind Sathgen Therapeutics (NSE: GODAVARIB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,988 Cr
+6.3% YoY
EBITDA
₹95.98 Cr
-7.4% YoY
Profit After Tax
₹33.63 Cr
+238.2% YoY
Net Worth
₹788 Cr
+0.8% YoY
Total Assets
₹1,332 Cr
+3.9% YoY
Total Debt
₹531 Cr
+8.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,9881,8701,6872,0151,7021,5381,459
Revenue growth+6.3%+10.9%-16.3%+18.4%+10.7%+5.4%-
EBITDA95.98104134146133158103
EBITDA margin+4.8%+5.5%+7.9%+7.3%+7.8%+10.3%+7.1%
Profit before tax4.57(1.55)12.4531.7532.0746.303.29
Net profit33.63(24.34)12.3920.2319.4526.380.31
Net profit margin+1.7%-1.3%+0.7%+1.0%+1.1%+1.7%+0.0%
EPS (₹)0.69(4.58)2.934.684.556.470.97
Balance sheet
Total assets1,3321,2811,1591,2281,1111,0281,029
Net worth788782501489473454427
Total debt531490655736636569589
Cash & bank32.1531.3832.5744.7846.7440.1444.06
Net working capital314393266331368280239
Cash flow
Cash from operations171(0.40)18519744.86130250
Cash from investing(163)(62.29)(43.99)(214)(47.67)(7.49)(22.60)
Cash from financing(5.74)63.83(151)28.435.95(121)(226)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue558564460431533580447321
Revenue growth (YoY)+4.6%-2.7%+2.8%+34.2%+2.1%---
Other income2.059.292.063.520.749.253.561.10
EBITDA0.5286.2135.20(34.59)5.7611236.11(32.63)
EBITDA margin+0.1%+15.3%+7.7%-8.0%+1.1%+19.4%+8.1%-10.2%
Depreciation14.4913.9213.5513.5213.5012.8412.3412.30
Interest13.9311.3010.2112.3215.3013.0718.8520.29
Profit before tax(25.85)70.2813.50(56.91)(22.30)95.748.48(64.12)
Tax(6.53)17.395.24(15.31)(6.29)23.812.7010.89
Net profit(19.32)52.898.26(41.60)(16.01)71.935.78(75.01)
EPS (₹)(3.78)10.331.61(8.13)(3.13)14.051.31(17.88)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,9651,8531,6752,0001,6911,5261,449
Revenue growth+6.0%+10.6%-16.2%+18.3%+10.8%+5.4%-
EBITDA92.83100132138130155102
EBITDA margin+4.7%+5.4%+7.9%+6.9%+7.7%+10.1%+7.0%
Profit before tax1.52(5.42)10.3523.4729.1243.381.66
Net profit31.99(2.62)10.6512.5116.6723.81(1.32)
Net profit margin+1.6%-0.1%+0.6%+0.6%+1.0%+1.6%-0.1%
EPS (₹)0.24(0.52)2.522.863.895.860.60
Balance sheet
Total assets1,3111,2711,1531,2261,1111,0271,031
Net worth773773494484474458434
Total debt525488655739634564584
Cash & bank19.0520.6322.6624.1438.2533.9639.56
Net working capital277366241322365266226
Cash flow
Cash from operations173(1.43)19618540.43129240
Cash from investing(163)(60.94)(45.13)(217)(46.53)(8.49)(27.81)
Cash from financing(9.50)62.67(151)31.396.93(120)(211)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue542562457423523576445316
Revenue growth (YoY)+3.6%-2.4%+2.6%+33.8%+1.4%---
Other income1.839.151.813.310.599.413.070.93
Total expenses544477422459518465408350
EBITDA(1.83)85.5434.99(35.80)4.7011036.89(34.08)
EBITDA margin-0.3%+15.2%+7.7%-8.5%+0.9%+19.1%+8.3%-10.8%
Depreciation14.4313.8713.5213.4713.4512.7912.2912.25
Interest13.8111.2510.0112.2214.9712.8719.0020.18
Profit before tax(28.24)69.5713.27(58.18)(23.13)93.968.67(65.58)
Tax(6.96)17.165.17(15.56)(6.48)23.882.5510.89

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue558564460431533580447321
Revenue growth (YoY)+4.6%-2.7%+2.8%+34.2%+2.1%---
Other income2.059.292.063.520.749.253.561.10
EBITDA0.5286.2135.20(34.59)5.7611236.11(32.63)
EBITDA margin+0.1%+15.3%+7.7%-8.0%+1.1%+19.4%+8.1%-10.2%
Depreciation14.4913.9213.5513.5213.5012.8412.3412.30
Interest13.9311.3010.2112.3215.3013.0718.8520.29
Profit before tax(25.85)70.2813.50(56.91)(22.30)95.748.48(64.12)
Tax(6.53)17.395.24(15.31)(6.29)23.812.7010.89
Net profit(19.32)52.898.26(41.60)(16.01)71.935.78(75.01)
EPS (₹)(3.78)10.331.61(8.13)(3.13)14.051.31(17.88)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,9881,8701,6872,0151,7021,5381,459
Revenue growth+6.3%+10.9%-16.3%+18.4%+10.7%+5.4%-
Other income12.2116.6614.408.397.658.2113.65
Total expenses1,8921,7671,5531,8681,5691,3811,356
Employee cost0.0011711111093.2879.4679.13
EBITDA95.98104134146133158103
EBITDA margin+4.8%+5.5%+7.9%+7.3%+7.8%+10.3%+7.1%
Depreciation54.4950.0659.9350.0848.0347.1344.95
Interest49.1371.7975.5672.7960.4472.3868.74
Profit before tax4.57(1.55)12.4531.7532.0746.303.29
Tax1.0421.880.1512.1212.9719.17(0.78)
Net profit33.63(24.34)12.3920.2319.4526.380.31
Net profit margin+1.7%-1.3%+0.7%+1.0%+1.1%+1.7%+0.0%
EPS (₹)0.69(4.58)2.934.684.556.470.97
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital51.1851.1841.9441.9441.9441.9441.94
Reserves & surplus737731459448431412385
Shareholders' funds (net worth)788782501489473454427
Minority interest0.000.000.000.000.000.000.00
Secured loans44137754968458348990.30
Unsecured loans89.4111310652.3652.6680.16499
Total debt531490655736636569589
Total liabilities1,3321,2811,1591,2281,1111,0281,029
Assets
Gross block1,3471,2971,2351,193946945926
Net block866862850866667708735
Capital work in progress14837.3828.7817.0450.358.6516.69
Investments0.050.000.000.000.000.050.05
Inventories776740805519652424383
Sundry debtors114138190202173169126
Cash & bank balances32.1531.3832.5744.7846.7440.1444.06
Loans & advances69.9711448.7458.1310860.2391.83
Total current assets9921,0231,076824979693644
Total current liabilities677630811493611413405
Net working capital314393266331368280239
Total assets1,3321,2811,1591,2281,1111,0281,029
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.2511.1121.2710.036.895.255.25
Net cash from operating activities171(0.40)18519744.86130250
Net cash from investing activities(163)(62.29)(43.99)(214)(47.67)(7.49)(22.60)
Net cash from financing activities(5.74)63.83(151)28.435.95(121)(226)
Net change in cash3.001.14(10.16)11.253.141.640.52
Closing cash32.1531.3832.5744.7846.7440.1444.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.3%+10.9%-16.3%+18.4%+10.7%+5.4%-
EBITDA growth-7.4%-22.4%-8.7%+10.0%-15.7%+52.5%-
PBT growth+9998.0%--60.8%-1.0%-30.7%+1307.3%+9997.0%
Net income growth+238.2%-296.5%-38.8%+4.0%-26.3%+8409.7%-
Revenue CAGR (3Y)-0.4%+3.2%+3.1%+11.4%---
EBITDA CAGR (3Y)-13.1%-8.0%-5.4%+12.3%---
Profitability & leverage
Net income margin+0.2%-1.3%+0.7%+1.0%+1.1%+1.8%+0.3%
Return on capital employed-+5.8%+7.4%+8.9%+8.7%+11.5%+6.6%
Return on net worth--3.7%+2.5%+4.1%+4.1%+6.2%+0.1%
Debt / equity-0.891.401.431.301.311.36
Long-term debt / equity-0.460.820.820.710.520.24
Interest cover118.41133.99102.6575.7071.2265.52117.75
Efficiency & per share
Fixed asset turnover-1.481.391.881.801.641.58
Inventory turnover-2.422.553.443.163.813.81
Debtors turnover-11.408.6110.759.9610.4311.61
EPS (₹)0.69(4.58)2.934.684.556.470.97
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00152.80119.37116.69112.77108.22101.84
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue542562457423523576445316
Revenue growth (YoY)+3.6%-2.4%+2.6%+33.8%+1.4%---
Other income1.839.151.813.310.599.413.070.93
Total expenses544477422459518465408350
EBITDA(1.83)85.5434.99(35.80)4.7011036.89(34.08)
EBITDA margin-0.3%+15.2%+7.7%-8.5%+0.9%+19.1%+8.3%-10.8%
Depreciation14.4313.8713.5213.4713.4512.7912.2912.25
Interest13.8111.2510.0112.2214.9712.8719.0020.18
Profit before tax(28.24)69.5713.27(58.18)(23.13)93.968.67(65.58)
Tax(6.96)17.165.17(15.56)(6.48)23.882.5510.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,9651,8531,6752,0001,6911,5261,449
Revenue growth+6.0%+10.6%-16.2%+18.3%+10.8%+5.4%-
Other income11.4616.0413.817.536.877.1112.73
Total expenses1,8721,7531,5441,8621,5611,3721,347
Employee cost0.0011711111093.1079.2778.97
EBITDA92.83100132138130155102
EBITDA margin+4.7%+5.4%+7.9%+6.9%+7.7%+10.1%+7.0%
Depreciation54.3249.8659.6349.5847.5046.7344.68
Interest48.4571.6175.5172.5360.0371.6468.00
Profit before tax1.52(5.42)10.3523.4729.1243.381.66
Tax0.30(2.74)(0.22)11.4512.7918.84(0.88)
Net profit31.99(2.62)10.6512.5116.6723.81(1.32)
Net profit margin+1.6%-0.1%+0.6%+0.6%+1.0%+1.6%-0.1%
EPS (₹)0.24(0.52)2.522.863.895.860.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital51.1851.1841.9441.9441.9441.9441.94
Reserves & surplus722721452442432416392
Shareholders' funds (net worth)773773494484474458434
Secured loans436376549629533484277
Unsecured loans89.4111310610910180.08307
Total debt525488655739634564584
Total liabilities1,3111,2711,1531,2261,1111,0271,031
Assets
Gross block1,3441,2941,2321,190943942923
Net block865862849866666706733
Capital work in progress14837.7429.1417.0450.358.6516.69
Investments16.0916.0416.0416.0414.0414.0213.94
Inventories760733802517652423381
Sundry debtors104130182212176162121
Cash & bank balances19.0520.6322.6624.1438.2533.9639.56
Loans & advances68.4811347.9360.8811059.3590.62
Total current assets9519961,054815976678632
Total current liabilities675630813493612412406
Net working capital277366241322365266226
Total assets1,3111,2711,1531,2261,1111,0271,031
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.501.200.631.540.700.270.87
Net cash from operating activities173(1.43)19618540.43129240
Net cash from investing activities(163)(60.94)(45.13)(217)(46.53)(8.49)(27.81)
Net cash from financing activities(9.50)62.67(151)31.396.93(120)(211)
Net change in cash0.650.300.57(0.91)0.840.440.40
Closing cash19.0520.6322.6624.1438.2533.9639.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.0%+10.6%-16.2%+18.3%+10.8%+5.4%-
EBITDA growth-7.2%-24.1%-4.6%+6.4%-16.1%+52.2%-
PBT growth+9998.0%--55.9%-19.4%-32.9%+2513.3%+9997.0%
Net income growth+1321.0%-124.6%-14.9%-25.0%-30.0%+1903.8%-
Revenue CAGR (3Y)-0.6%+3.1%+3.2%+11.4%---
EBITDA CAGR (3Y)-12.4%-8.3%-5.2%+10.8%---
Profitability & leverage
Net income margin+0.1%-0.1%+0.6%+0.6%+1.0%+1.6%+0.2%
Return on capital employed-+5.5%+7.2%+8.2%+8.3%+11.2%+6.0%
Return on net worth--0.4%+2.2%+2.5%+3.5%+5.5%-0.3%
Debt / equity-0.901.421.431.291.291.71
Long-term debt / equity-0.470.830.820.710.510.32
Interest cover125.81142.79104.8081.9872.9666.39119.44
Efficiency & per share
Fixed asset turnover-1.471.381.881.791.641.65
Inventory turnover-2.422.543.423.153.803.05
Debtors turnover-11.908.5010.309.9910.7911.15
EPS (₹)0.24(0.52)2.522.863.895.860.60
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.00150.97117.87115.49113.08109.21103.47
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sathgen Therapeutics

Godavari Biorefineries: Co Mexican Patent Office Awards Patent For Using Compounds To Treat Viral Infections By Inhibiting V-ATPase Activity In Cells.
Exchange Update • 1 month ago
Godavari Biorefineries secures a Chinese patent for viral infection treatment compounds - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Godavari Biorefineries receives Chinese patent for use of compounds for treatment of viral infection | Capital Market News - Business Standard
Business Standard • 1 month ago
Godavari Biorefineries jumps on bagging Chinese patent for antiviral compound | Capital Market News - Business Standard
Business Standard • 1 month ago
Godavari Biorefineries jumps nearly 10% after Chinese patent grant for antiviral compound - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Godavari Biorefineries share price rallies 13% after Chinese patent grant | Do you own? | Stock Market News
mint • 1 month ago
Godavari Biorefineries shares surge 13% after China grants patent for viral infection treatment - CNBC TV18
CNBCTV18 • 1 month ago
Godavari Biorefineries: Co. Receives Patent Approval From Chinese Office For Viral Infection Treatment Compounds.
Exchange Update • 1 month ago
Godavari Biorefineries gets European patent for biofiller for rubber reinforcement - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Godavari Biorefineries secures European patent for anti-cancer drug composition - The HinduBusinessLine
Thehindubusinessline • 2 months ago
Premium access

Complete news archive for Sathgen Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sathgen Therapeutics

Sathgen Therapeutics was founded in 2007.

Sathgen Therapeutics is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Sathgen Therapeutics has 1,482 employees.

The primary company behind Sathgen Therapeutics, Godavari Biorefineries Limited, reported revenue of ₹2,000 Cr for FY 2026, up 6% year on year.

Sathgen Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative treatments for difficult-to-treat cancers and viral infections. They conduct clinical trials for their lead drug candidate, MSP008-22, to evaluate safety and efficacy. Backed by Godavari Biorefineries Limited, they use an integrated approach to target diseases as complex systems. Based in Mumbai, India, they collaborate with partners to improve patient quality of life.

Sathgen Therapeutics offers MSP008-22.

Yes, Sathgen Therapeutics is publicly traded on NSE under the ticker symbol GODAVARIB.

Sathgen Therapeutics operates through Godavari Biorefineries Limited.

The legal entities of Sathgen Therapeutics currently have 16 directors, including Lakshmi Kantam Mannepalli, Suhas Uttam Godage, Swarna Shivaji Gunware and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available